Tag

Orforglipron

All articles tagged with #orforglipron

health4 days ago•5 min saved

Personal Trial: An Endocrinologist Takes an Oral GLP-1 to Potentially Prevent Dementia

An endocrinologist shares a personal choice to start orforglipron, an oral GLP-1, at age 48 to potentially reduce dementia risk after watching her mother’s Alzheimer’s progression. She notes no proven dementia prevention data yet, but cites brain-related mechanisms, observational signals of lower dementia rates with GLP-1s, and mixed trial results. The decision is deeply personal, balancing evolving science with family history and broader health goals, while continuing other healthy aging practices.

via Medscape|

#alzheimers-disease #dementia-prevention #glp-1-receptor-agonists

health13 days ago•4 min saved

Orforglipron tops oral GLP-1 rivals in 52-week diabetes trial

A 52-week Phase 3 trial in 1,698 adults with type 2 diabetes found that Eli Lilly’s orforglipron, an oral small‑molecule GLP-1 drug, reduced HbA1c by about 1.71–1.91 percentage points and produced greater weight loss (6.1–8.2 kg) compared with oral semaglutide (1.47 HbA1c reduction and ~5.3 kg weight loss). However, tolerability favored semaglutide, with around 59% reporting GI side effects on orforglipron versus 37–45% on semaglutide and higher discontinuation (~10% vs ~4–5%). Orforglipron’s small‑molecule, no‑refrigeration profile could improve access in lower‑income countries, but there’s no head‑to‑head with injectable GLP‑1s yet and long‑term adherence remains to be seen.

via ScienceDaily|

#glp-1 #hba1c #health

health1 month ago•7 min saved

Beyond GLP-1: Endoscopic and Oral Options to Sustain Weight Loss

Real-world data show weight loss from GLP-1 therapy is often not sustained after discontinuation, with most patients regaining weight and metabolic benefits fading within about 1.4 years. Emerging strategies—endoscopic approaches such as endoscopic sleeve gastroplasty, duodenal mucosal resurfacing, and the newly approved oral GLP-1 orforglipron—offer potential for longer-term maintenance, but cost, insurance coverage, and access remain barriers. When cost is considered, bariatric surgery can be more cost-effective long term; more head-to-head studies and guidelines are needed to define optimal maintenance after GLP-1 therapy.

via Medscape|

#duodenal-mucosal-resurfacing #endoscopic-sleeve-gastroplasty #glp-1

health2 months ago•9 min saved

New pill could sustain weight loss after GLP-1 injections

Orforglipron, a once-daily small-molecule pill that targets the GLP-1 system and has FDA approval for obesity, may help people keep most of their weight loss after stopping injections like Wegovy or Mounjaro. In a randomized trial, those who switched to orforglipron regained about 26% of lost weight (vs over 50% on placebo) after 52 weeks, with more than two-fifths maintaining at least 80% of their weight loss and improved health markers such as blood sugar, blood pressure, insulin and cholesterol. The pill could be cheaper and easier to store than peptide injections, but it is not yet licensed in the UK for weight loss, and US monthly costs are roughly $149–$299.

via The Conversation|

#glp-1 #health #obesity

health2 months ago•4 min saved

New Pill Could Sustain GLP-1 Weight Loss and Lower Costs

Orforglipron, a once-daily pill-based GLP-1 weight‑loss drug, could sustain weight loss and cut costs versus injections like Wegovy and Mounjaro. In a small trial, switching to orforglipron after initial weight loss reduced weight regain markedly (about 26% with orforglipron vs 50%+ on placebo for Mounjaro; about 21% vs 62% for Wegovy) while preserving health benefits; US monthly price is roughly $149–$299 vs over $1,000 for Mounjaro, and the UK has not yet licensed it but expects approval around late 2026–early 2027.

via ScienceAlert|

#affordability #glp-1 #health

health2 months ago•3 min saved

New daily pill may lock in weight loss after obesity injections

A new daily pill, orforglipron, could help people maintain weight loss after stopping GLP-1 obesity injections. In a Nature Medicine trial, participants who took orforglipron for a year kept more than 70% of their earlier weight loss, versus about 38-50% for those on placebo; side effects were mostly mild. The long-term durability, duration of treatment, and cost (UK pricing not yet known) remain unclear, but experts say this supports the view that obesity is a chronic condition requiring ongoing management.

via BBC|

#clinical-trial #glp-1 #health

healthcare3 months ago•14 min saved

Lilly’s Foundayo earns non-inferiority and cardiometabolic gains in ACHIEVE-4, fueling FDA submission

In ACHIEVE-4, the largest/longest Phase 3 trial of Foundayo (orforglipron) vs insulin glargine in adults with type 2 diabetes at high CV risk, Foundayo met non-inferiority for MACE-4 and showed 16% lower risk for MACE-4 and 23% lower risk for MACE-3; a pre-planned analysis also showed 57% lower risk of all-cause death. The study (2,700+ participants across 15 countries) demonstrated sustained A1C and body-weight improvements through 104 weeks. Lilly intends to submit Foundayo to the FDA for type 2 diabetes by end of Q2.

via Eli Lilly|

#achieve-4 #cardiovascular-safety #foundayo

health3 months ago•6 min saved

New Oral GLP-1 Pill Shifts the Weight-Loss Race Against Ozempic

A 52-week phase-3 trial in 1,698 adults with type 2 diabetes across six countries found orforglipron, a daily oral small-molecule GLP-1 drug, reduced HbA1c more and produced greater weight loss than oral semaglutide (1.71–1.91% vs 1.47% HbA1c and 6.1–8.2 kg vs 5.3 kg), but caused more gastrointestinal side effects and higher discontinuation (~10% vs 4–5%). It’s cheaper to manufacture and doesn’t require refrigeration, giving it logistical advantages, though long-term comparisons with injectable GLP-1 therapies and obesity trials without diabetes are still underway.

via ScienceAlert|

#diabetes #glp-1 #health

health4 months ago•1 min saved

Oral GLP-1 Weight-Loss Pills Break Through, Shifting the Injectable Era

STAT News explains why turning GLP-1 weight‑loss drugs into pills has been so challenging, highlighting Novo Nordisk’s Wegovy oral version and Lilly’s orforglipron, and what the shift could mean for pricing and accessibility as these pills head toward approval.

via statnews.com|

#glp-1 #health #oral-pills

business4 months ago•5 min saved

Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial

In a year-long, head-to-head trial with 1,698 diabetes patients, Eli Lilly’s oral GLP-1 pill orforglipron outperformed Novo Nordisk’s Rybelsus on blood sugar control and weight loss (roughly 15–20 lbs vs 8–11 lbs), with better cardiovascular markers. Higher doses brought more GI side effects (about 10% dropout). The pill can be taken anytime, doesn’t require refrigeration, and Lilly aims for U.S. availability by mid-2026 at about $145–$399 out of pocket.

via Business Insider|

#business #diabetes #glp-1

business5 months ago•3 min saved

Medicare tailwinds could accelerate Lilly’s obesity-pill rollout

Eli Lilly CEO Dave Ricks says Medicare coverage of obesity treatments later this year could be a major catalyst for the launch of orforglipron, with a full rollout planned in Q2 and price reductions expected in the second half under Trump-era deals; the move could expand access to 20–30 million beneficiaries and follows strong early demand for competitor Wegovy, a GLP-1 obesity pill.

via CNBC|

#business #eli-lilly #glp-1

health6 months ago•6 min saved

Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss

Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.

via Gizmodo|

#cagrisema #glp-1-therapy #health

healthcare7 months ago•22 min saved

Eli Lilly's Oral GLP-1 Therapy Sustains Weight Loss Post-Injection

Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully maintained weight loss in a Phase 3 trial after patients switched from injectable therapies, leading Lilly to submit it for FDA approval as a treatment for obesity.

via Eli Lilly|

#healthcare #lilly #obesity

healthcare9 months ago•8 min saved

Lilly's Orforglipron Excels in Phase 3 Trials for Type 2 Diabetes

Eli Lilly's oral GLP-1 receptor agonist, orforglipron, showed superior glycemic control in two Phase 3 trials, outperforming dapagliflozin and oral semaglutide, with significant A1C reductions and weight loss, supporting its potential as a new standard treatment for type 2 diabetes.

via investor.lilly.com|

#glycemic-control #healthcare #lilly

health10 months ago•4 min saved

Lilly's New GLP-1 Pill Outperforms Competitors in Weight Loss and Diabetes Trials

A new oral GLP-1 agonist, orforglipron, has shown promising results in a large trial, helping obese patients lose up to 11% of their body weight over 72 weeks, offering a potentially more accessible alternative to injectable treatments, with significant improvements in cardiometabolic health markers.

via SciTechDaily|

#glp-1 #health #obesity